Results 31 to 40 of about 15,879 (168)
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang +8 more
wiley +1 more source
Full androgen deprivation (FAD) induces paracrine cholesterol in prostate cancer that drives the polarization of cancer‐associated fibroblasts (CAFs) and subsequent elevated matrix stiffness. Matrix stiffness in turn potentiates tumor cell survival under FAD pressure via dual mechanotransductive activation of the IRE1α‐XBP1s stress‐response axis ...
Shaojie Liu +20 more
wiley +1 more source
Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer [PDF]
Objective To investigate the short-term efficacy and safety of enzalutamide in the treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC).
MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
doaj +1 more source
Our experimental evidence supports a model in which ALO targets the HSPA8‐CMA‐ATP6V1A axis to induce lysosomal hyperacidification and initiate osmotic and lipidomic stress. These changes are associated with LMP and loss of lysosomal integrity in prostate cancer cells.
Bingzheng An +8 more
wiley +1 more source
CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer
Prostate cancer cell lines of differing origins were cultured over many passages while being subjected to semi‐lethal levels of fluid shear stress, representing the harsh mechanical environment these cells are subjected to in the circulation during the process of distant metastasis.
Abigail R. Fabiano +10 more
wiley +1 more source
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to progression despite androgen deprivation therapy (ADT).
Rafał B. Drobot +2 more
doaj +1 more source
Background This study investigated how differences in the method of the first‐line androgen deprivation therapy (ADT) affected the time to castration‐resistant prostate cancer.
Mizuki Onozawa +11 more
doaj +1 more source
Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
Metastatic castration-resistant prostate cancer (mCRPC) is an extremely severe disease that relentlessly evolves to death. Over the past few years, we have seen significant improvements in the different types of treatments available, which have ...
Rodrigo Bovolin de Medeiros +3 more
doaj +1 more source
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source

